title: Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2.
abstract: Preliminary studies have suggested that the intracavitary administration of cytokines may represent a new effective palliative therapy of malignant effusions. To define further the therapeutic role of cytokines in the treatment of neoplastic fluid accumulation, 70 cancer patients with pleural, pericardial or peritoneal cytologically proven neoplastic effusions were randomized to receive intracavitary cycles with interleukin-2 (IL-2; 6 x 10(6) IU), interferon (IFN alpha; 2 x 10(7) U) or IFN beta (6 x 10(6) U) every week for 2 or 3 weeks. A clinical control of fluid accumulation was obtained in 39/70 (56%) patients. In patients with mesothelioma, the response rate was significantly higher with IL-2 than with IFN alpha or -beta, while there was no difference in patients with tumors other than mesothelioma. Moreover, the duration of the period during which drainage was not required was significantly longer in patients treated with Il-2 than in the other groups. Toxicity was low in all patients. According to preliminary data, this study demonstrates that intracavitary administration of cytokines, including IL-2, IFN alpha and -beta, is a new well-tolerated palliative therapy for malignant effusions, with an efficacy substantially comparable to that described with the most commonly used treatments with tetracyclines or cytostatic agents.
authors.affiliation: Division of Radiation Oncology, San Gerardo Hospital, Monza (Milan), Italy.
authors.forename: P
authors.initials: P
authors.lastname: Lissoni
authors.forename: S
authors.initials: S
authors.lastname: Barni
authors.forename: G
authors.initials: G
authors.lastname: Tancini
authors.forename: A
authors.initials: A
authors.lastname: Ardizzoia
authors.forename: E
authors.initials: E
authors.lastname: Tisi
authors.forename: M
authors.initials: M
authors.lastname: Angeli
authors.forename: A
authors.initials: A
authors.lastname: Rizzi
mesh_terms: D000328:Adult; D000368:Aged; D001202:Ascitic Fluid / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D016207:Cytokines / Q000008:administration & dosage / Q000627:therapeutic use*; D004322:Drainage; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*; D010490:Pericardial Effusion / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D016066:Pleural Effusion, Malignant / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D016207:Cytokines; D016898:Interferon-alpha; D007376:Interleukin-2; D016899:Interferon-beta